Morgan Stanley Trims InterMune Estimates

Analyst Caroline Copithorne cites disappointing Phase III trial data for the company's lung disease drug

Morgan Stanley cut its estimates on InterMune (ITMN ).

To continue reading this article you must be a Bloomberg Professional Service Subscriber.